DAYTRANA (methylphenidate)
Daytrana is a central nervous system stimulant that treats Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents between the ages of 6 and 17. This medication helps patients with their symptoms through a transdermal system. It is not recommended for children under 6 years old because younger patients may experience higher drug levels and more side effects like weight loss.
How DAYTRANA Works
This medication works by acting as a central nervous system stimulant. While it contains methylphenidate, the specific way this drug produces its therapeutic effect in patients with ADHD is not currently known.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2006-04-06
- PDUFA Date
- 2026-05-31 (5d)
- Routes
- TRANSDERMAL
- Dosage Forms
- FILM, EXTENDED RELEASE
DAYTRANA Approval History
What DAYTRANA Treats
1 indicationsDAYTRANA is approved for 1 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Attention Deficit Hyperactivity Disorder
DAYTRANA Boxed Warning
ABUSE, MISUSE, AND ADDICTION DAYTRANA has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction. Educate patient...
WARNING: ABUSE, MISUSE, AND ADDICTION DAYTRANA has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout DAYTRANA treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning DAYTRANA has high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death ( 5.1 , 9.2 , 10 ): Before prescribing DAYTRANA, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
DAYTRANA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to DAYTRANA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
78 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07314333 | 405-201-00198 | Ph 1 | completed | A Trial to Assess How Centanafadine Interacts With Stimulants in the Body |
| NCT03772834 | 2018-0559 NCI-2018-02527, 2018-0559 | Ph 2, Ph 3 | active not recruiting | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer |
| NCT04419272 | NURD-003-22S CX002474 | Ph 4 | recruiting | Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits |
| NCT03525873 | 2017-0913 NCI-2018-00698, 2017-0913 | Ph 3 | active not recruiting | A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy |
| NCT01410942 | 2011-0389 RSG-11-170-01-PCSM, NCI-2011-02764 | Ph 2 | active not recruiting | Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy |
| NCT07301632 EASEPain | EASE Pain P-006 | Ph 2 | recruiting | Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial |
| NCT03652740 results posted | IRB00165287 R01DA003890 | Ph 1 | completed | Effects of Commonly Used Medications on Mood and Choice |
| NCT05776056 IMPACT | MHBP-006-22S CX002546 | Ph 4 | recruiting | Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints |
| NCT03280251 PACTE-1 | 2015_81 2016-005131-32 | Ph 2 | completed | Methylphenidate and Cognitive Training in Elderly |
| NCT06081179 | 2A-SC-1 | Ph 1 | completed | Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans |
| NCT05474846 | 2022-0180 NCI-2022-06045 | Ph 2, Ph 3 | recruiting | Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer |
| NCT03814356 STIMPACT results posted | 140675 DP2HD101400 | Ph 1 | active not recruiting | Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness |
| NCT04781972 | IRB00276357 | Ph 4 | recruiting | Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD |
| NCT06355414 | IRB00385932 R33AT012317 | Ph 1 | recruiting | Psilocybin in Chronic Low Back Pain and Depression |
| NCT06580041 | 24-41815 | Ph 4 | enrolling by invitation | Precision Care for Major Depressive Disorder |
| NCT04885257 results posted | MHBP-011-20F IK2CX002104 | Ph 1, Ph 2 | completed | Methylphenidate for Ptsd and Stroke Veterans |
| NCT04421248 AMPAIII | CHMC IRB 2020-0297 | Ph 4 | recruiting | Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder |
| NCT03575403 BED[IN]:36 results posted | 44796 R01AA026255 | Ph 1 | completed | Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate) |
| NCT05133804 | LH9/2019 | Ph 2 | recruiting | Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD |
| NCT05285683 | STUDY00006948 | Ph 2 | recruiting | The Role of Brain Dopamine in Chronic Pain |
| NCT05957055 LAMAinDiab | LAMA/2021/1 2022-001906-24, 2021/ABM/02/00006/P/03 | Ph 2 | recruiting | Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes |
| NCT00792662 | 0470-08-FB | Ph 4 | withdrawn | Improving Function, Quality of Life, Glycemia in Diabetics With Dementia |
| NCT03781752 | GCO 17-0281 1R01HD093612-01A1 | Ph 4 | recruiting | Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD |
| NCT03781765 MPH-ATX | GCO 17-0423 1R21DA045218-01A1 | Ph 4 | recruiting | Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk |
| NCT04273880 | H13-00286 5R01DA037285-05 | Ph 1 | recruiting | Differences by Sex and Genotype in the Effects of Stress on Executive Functions |
| NCT05669924 | STU00213557 | Ph 2 | completed | Neural Correlates of Acute Pain Dynamics |
| NCT06077669 | IRB00408678 | Ph 4 | withdrawn | Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD |
| NCT00754208 results posted | 0380-08-FB | Ph 4 | completed | Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children |
| NCT02346201 ADMET2 results posted | ADMET2 R01AG046543 | Ph 3 | completed | Apathy in Dementia Methylphenidate Trial 2 |
| NCT02477280 | 2015-03-10/11 2014-001488-11 | Ph 4 | completed | Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance |
| NCT02153944 results posted | 140114 14-M-0114 | Ph 4 | completed | Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety |
| NCT02502799 results posted | DA034731 | Ph 3 | terminated | Intervention for Teens With ADHD and Substance Use |
| NCT01978431 | 1001006250 R25MH071584 | Ph 1 | completed | Impulsivity and Stimulant Administration |
| NCT04178993 results posted | BED(IN):40 R01DA047391 | Ph 1 | completed | Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] |
| NCT05669170 MAV-PD | CX002673-01 | Ph 2 | not yet recruiting | Methylphenidate for Apathy in Veterans With Parkinson's Disease |
| NCT03481959 METHACAN | P140313 | Ph 3 | terminated | Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity |
| NCT02700685 | Pycno 2015-14 | Ph 3 | completed | Effect of Pycnogenol® on ADHD |
| NCT04349917 results posted | 16-0112 R00MH102349 | Ph 4 | completed | Large-scale Brain Organization During Cognitive Control in ADHD |
| NCT03185065 TRIUMPHANT-MS results posted | IRB00119702 | Ph 3 | completed | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis |
| NCT02807870 | 466859/2014-7 | Ph 4 | completed | Early Interventions in Children With Attention Deficit/Hyperactivity Disorder |
| NCT02039908 results posted | MH099030 | Ph 4 | completed | Examining Tolerance to CNS Stimulants in ADHD |
| NCT01933217 results posted | 1K23HD074683-01A1 | Ph 4 | completed | Methylphenidate for Attention Problems After Pediatric TBI |
| NCT02063945 | SHEBA-13-0564-DG-CTIL | Ph 4 | terminated | Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders |
| NCT02225106 DAPET-TBI results posted | 140169 14-N-0169 | Ph 2 | completed | Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI |
| NCT02051452 results posted | 2013P001114 | Ph 1, Ph 2 | completed | Reversal of General Anesthesia With Methylphenidate |
| NCT01164956 results posted | 10-146 | Ph 1 | terminated | Methylphenidate for Cancer-Related Fatigue |
| NCT02227056 | loe130007ctil | Ph 2 | completed | Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population |
| NCT02148783 | 402693-1 HJF grant | Ph 2 | terminated | Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI |
| NCT02675400 | Fathers Too | Ph 4 | completed | Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too) |
| NCT02473185 | 2015-03-10/53 2014-005045-53 | Ph 4 | completed | Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest |
Showing 50 of 78 trials
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DAYTRANA FDA Label Details
Indications & Usage
FDA Label (PDF)DAYTRANA is indicated for the treatment of Attention Deficit Hyperactivity Disorder.
WARNING: ABUSE, MISUSE, AND ADDICTION DAYTRANA has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death [see Overdosage ( 10 )] , and this risk...
Track DAYTRANA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment